Table 5.

Genitourinary tract bleeding among DOAC using patients.

Urogenital tract bleeding
	Concurrent statin	No. of PQs	No. of events	Crude incidence rate (per 1,000 person-year) (95% CI)	Adjusted incidence rate (per 1,000 person-year) (95% CI)	Adjusted IRR (95% CI)	Adjusted IRD (per 1,000 person-year) (95% CI)
All	No statin	332259	425	5.12 (4.64–5.66)	4.46 (3.94–5.05)	1
	All intensity	238923	250	4.19 (3.68–4.77)	4.19 (3.68–4.77)	0.94 (0.79–1.12)	−0.27 ( −1.04 to 0.50)
	High-intensity	79266	79	4.00 (3.20–4.99)	3.99 (3.20–4.99)	0.92 (0.72 −1.19)	−0.32 (−1.37 to 0.72)
	Low-to-moderate-intensity	165474	176	4.26 (3.64–4.97)	4.26 (3.64–4.97)	0.94 (0.77 −1.15)	−0.26 (−1.12 to 0.61)
Male	No statin	190084	288	6.07 (5.38–6.85)	5.48 (4.72–6.37)	1
	All intensity	135304	182	5.39 (4.63–6.28)	5.39 (4.63–6.28)	0.98 (0.79 −1.22)	−0.09 (−1.25 to 1.07)
	High-intensity	45017	52	4.63 (3.53–6.07)	4.63 (3.53–6.07)	0.87 (0.64 −1.19)	−0.68 (−2.17 to 0.82)
	Low-to-moderate-intensity	93569	135	5.78 (4.83–6.92)	5.78 (4.83–6.92)	1.04 (0.83 −1.32)	0.24 (−1.09 to 1.56)
Female	No statin	141669	137	3.87 (3.24–4.62)	3.37 (2.69–4.22)	1
	All intensity	103070	68	2.64 (2.07–3.35)	2.64 (2.07–3.35)	0.79 (0.57 −1.10)	−0.7 (−1.69 to 0.29)
	High-intensity	34017	27	3.18 (2.16–4.70)	3.18 (2.15–4.69)	0.99 (0.63 −1.56)	−0.02 (−1.46 to 1.42)
	Low-to-moderate-intensity	71558	41	2.29 (1.69–3.10)	2.29 (1.69–3.11)	0.68 (0.46 −0.99)	−1.08 (−2.11 to −0.05)

DOAC, direct oral anticoagulant; PQ, person-quarter; CI, confident interval; IRR, incidence rate ratio; IRD, incidence rate difference.